SSY Group gains NMPA approval for multiple new drugs in China

SSY Group Limited has announced the approval for drug production and registration of Aminophylline Tablets (100mg) by China's National Medical Products Administration (NMPA). This type 3 chemical drug, primarily used for respiratory conditions such as bronchial asthma and emphysema, is regarded as passing the consistency evaluation. The group’s Aminophylline bulk drug also received NMPA approval for registration.

Furthermore, SSY Group secured NMPA approvals for Procaterol Hydrochloride Inhalation Solution (0.5ml: 50µg) and Ademetionine 1,4-Butanedisulfonate for Injection (0.5g). These are classified as type 3 and type 4 chemical drugs, respectively, and both have passed the consistency evaluation.

Procaterol Hydrochloride Inhalation Solution is indicated for various symptoms associated with airflow limitation in bronchial asthma and chronic bronchitis, while Ademetionine 1,4-Butanedisulfonate for Injection targets intrahepatic cholestasis. These approvals represent a significant expansion of SSY Group’s product portfolio in the Chinese market.